The content on this site is intended for healthcare professionals only
Implementing national cancer control plans
Comment: POLO III trial for metastatic pancreatic cancer
Getting high level care to low and middle income countries
Tackling the increase in cancer cases worldwide
How will ASCO combat cancer disparities?
PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer
Are PARP inhibitors a new standard of care option for MBC patients?
The potential of PARP inhibitors in new cancer groups and in combination with other treatments
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions
Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients
Cancer care in low and middle income countries
Cancer care in Latin America
Surveying cancer patients' mental health and financial problems
Implementing better cancer diagnosis in low and middle income countries
Project Pink Blue: Fighting cancer through increasing awareness, screening, advocacy and patient navigation
Challenges in global cancer control
Novel methods of drug testing and biopsy in India
Cutting-edge cancer care at the Miami Cancer Institute
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma
NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer?
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer
Comment: Chemotherapy for frail and elderly patients with advanced gastroesophageal cancer
Comment: Laparoscopic versus open resection for colorectal liver metastases
CheckMate-142: Updated data from MSI high metastatic colon cancer patients
Advances in PARP inhibitor use for metastatic breast cancer
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer
Margetuximab for the treatment of HER2-positive breast cancer
The future of PARP inhibitors in metastatic breast cancer
DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer
EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer
ECHO palliative care in Africa: Improving access to quality palliative care
Developments in neoadjuvant immunotherapy options for early-stage lung cancer patients
Implementing the Breast Health Global Initiative guidelines
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC
Expanding clinical trial eligibility criteria: Risks and solutions
Pembrolizumab increases long-term survival in patients with advanced NSCLC
Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer
ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer
ASCO 2019 and vision for cancer control
Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial
Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer
Guiding treatment decisions through the use of molecular profiling in breast cancer
Managing metastatic breast cancer and beyond using PARP inhibitors
Updates in metastatic and early-stage breast cancer
PARP inhibitors in metastatic breast cancer: Where are we now?
ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies
Updates in the management of pancreatic cancer from ASCO 2019
Genetic testing and PARP inhibitors in metastatic prostate cancer
Metastatic castration resistant prostate cancer: Updates from ASCO 2019
Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma
Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma
POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer
Breast cancer highlights from ASCO 2019
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma
FORTE trial results: KRd with or without transplantation in newly diagnosed myeloma according to risk status
Carfilzomib and irinotecan in relapsed small cell lung cancer
Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer
CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM
ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcomas
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC
ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia
Highlights from ASCO 2019
Preventing brain metastases in patients with HER2 or triple negative breast cancer
Potential of PARP inhibitors for metastatic breast cancer
Understanding eligibility criteria for clinical trials to increase study size
Long-term survival after laparoscopic versus open resection for colorectal liver metastases
Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer
Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer
No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations
Enzalutamide as treatment for men with mHSPC who have received testosterone suppression
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life
Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer
Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent
Improving cancer care outcomes in Ghana through mentorship
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab
AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC
PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC
Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients
Comment: The success of immunotherapy means we have to change our mindset as we treat patients
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers
